RxDoctor Payments Data

Jaclyn Harrison, MD

Internal Medicine · Houston, TXNPI 1760616163

Payments from drug & device makers

$1,717in general payments, 2019–2025

Across 88 payments — averaging $19.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$425
  • Novo Nordisk$361
  • Lilly USA, LLC$189
  • Astellas Pharma US Inc$104
  • Pfizer$100
  • Dexcom, Inc.$95
  • plus $444 from 9 others

What the payments were for

  • Food & beverage$1,717100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,717 in reported general payments places this provider in the 75th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$76,825
Medicare patients
147
Services billed
1,269

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide82$108,339
TrulicityDulaglutide42$72,172
OzempicSemaglutide47$61,508
RybelsusSemaglutide24$54,525
FarxigaDapagliflozin Propanediol36$36,313
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$35,584
EliquisApixaban22$23,373
JardianceEmpagliflozin14$18,644
ArexvyRsvpref3 Antigen/As01e/Pf24$7,397
ShingrixVaricella-Zoster Ge/As01b/Pf20$4,397
Atorvastatin Calcium263$1,960
Celecoxib28$1,522
Losartan Potassium139$1,368
Gabapentin79$1,299
Estradiol19$1,223

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$189$180,511124 claims
Novo NordiskOzempic, Rybelsus$361$116,03371 claims
GSKTrelegy Ellipta, Arexvy, Shingrix$76$47,37770 claims
AstraZenecaFarxiga$425$36,31336 claims
PfizerEliquis$100$23,37322 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →